New York State Common Retirement Fund Has $7.21 Million Position in Integra LifeSciences Holdings Corporation (IART)

New York State Common Retirement Fund lifted its position in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 1.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 132,266 shares of the life sciences company’s stock after buying an additional 1,899 shares during the quarter. New York State Common Retirement Fund owned about 0.17% of Integra LifeSciences Holdings Corporation worth $7,210,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. Acrospire Investment Management LLC grew its stake in shares of Integra LifeSciences Holdings Corporation by 280.0% in the second quarter. Acrospire Investment Management LLC now owns 1,900 shares of the life sciences company’s stock valued at $104,000 after buying an additional 1,400 shares in the last quarter. Thrivent Financial For Lutherans grew its stake in shares of Integra LifeSciences Holdings Corporation by 8.5% in the second quarter. Thrivent Financial For Lutherans now owns 36,660 shares of the life sciences company’s stock valued at $1,998,000 after buying an additional 2,880 shares in the last quarter. Westfield Capital Management Co. LP grew its stake in shares of Integra LifeSciences Holdings Corporation by 16.3% in the second quarter. Westfield Capital Management Co. LP now owns 794,716 shares of the life sciences company’s stock valued at $43,320,000 after buying an additional 111,091 shares in the last quarter. Amalgamated Bank grew its stake in shares of Integra LifeSciences Holdings Corporation by 6.6% in the second quarter. Amalgamated Bank now owns 8,510 shares of the life sciences company’s stock valued at $464,000 after buying an additional 524 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its stake in shares of Integra LifeSciences Holdings Corporation by 2.9% in the second quarter. Ameriprise Financial Inc. now owns 434,993 shares of the life sciences company’s stock valued at $23,709,000 after buying an additional 12,212 shares in the last quarter. 84.90% of the stock is owned by institutional investors and hedge funds.

In other news, Director Donald E. Morel, Jr. purchased 2,500 shares of the business’s stock in a transaction dated Thursday, August 3rd. The stock was bought at an average price of $49.29 per share, for a total transaction of $123,225.00. Following the purchase, the director now owns 29,612 shares of the company’s stock, valued at $1,459,575.48. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Donald E. Morel, Jr. purchased 10,000 shares of the business’s stock in a transaction dated Friday, August 4th. The shares were purchased at an average price of $49.25 per share, with a total value of $492,500.00. Following the purchase, the director now directly owns 29,612 shares in the company, valued at approximately $1,458,391. The disclosure for this purchase can be found here. Insiders acquired a total of 17,550 shares of company stock valued at $864,842 in the last 90 days. Corporate insiders own 21.50% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.com-unik.info/2017/10/12/new-york-state-common-retirement-fund-has-7-21-million-position-in-integra-lifesciences-holdings-corporation-iart.html.

Several equities analysts recently weighed in on the stock. BidaskClub cut shares of Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Oppenheimer Holdings, Inc. set a $60.00 target price on shares of Integra LifeSciences Holdings Corporation and gave the company a “buy” rating in a research note on Saturday, June 24th. Cantor Fitzgerald assumed coverage on shares of Integra LifeSciences Holdings Corporation in a research note on Thursday, June 29th. They issued an “overweight” rating and a $65.00 target price for the company. Barclays PLC reissued an “equal weight” rating and issued a $53.00 target price (up from $47.00) on shares of Integra LifeSciences Holdings Corporation in a research note on Tuesday, September 12th. Finally, Jefferies Group LLC reissued a “buy” rating on shares of Integra LifeSciences Holdings Corporation in a research note on Sunday, September 10th. Four research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $54.27.

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) opened at 49.59 on Thursday. The firm’s 50-day moving average price is $50.62 and its 200 day moving average price is $49.35. The firm has a market cap of $3.87 billion, a P/E ratio of 60.48 and a beta of 0.71. Integra LifeSciences Holdings Corporation has a one year low of $37.71 and a one year high of $56.42.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last announced its quarterly earnings data on Wednesday, July 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.45. The firm had revenue of $282.16 million during the quarter, compared to the consensus estimate of $283.58 million. Integra LifeSciences Holdings Corporation had a return on equity of 16.79% and a net margin of 6.27%. The business’s revenue for the quarter was up 13.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.40 EPS. Analysts predict that Integra LifeSciences Holdings Corporation will post $1.91 EPS for the current year.

Integra LifeSciences Holdings Corporation Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Corporation (NASDAQ:IART).

Institutional Ownership by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

What are top analysts saying about Integra LifeSciences Holdings Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Integra LifeSciences Holdings Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit